GlassScriptPhysician profile
Jason R Conn
NPI 1336218437
$8,855.87
in general payments reported to CMS, 2019-2025
50 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $376 · 2021: $1,843 · 2022: $1,167 · 2023: $1,342 · 2024: $1,656 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,545.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,222.07 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $935.23 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $812.76 | 2020-2025 | Caplyta |
| Corium, LLC | $693.06 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $583.97 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $357.68 | 2023-2025 | Sunosi, Auvelity |
| Janssen Pharmaceuticals, INC | $327.43 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $257.05 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $241.73 | 2019-2025 | Trintellix |
| Alkermes, INC. | $240.78 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $239.83 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $175.84 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $175.57 | 2019 | |
| Allergan, INC. | $175.34 | 2019-2020 | |
| Noven Therapeutics, LLC | $169.92 | 2020-2025 | Xelstrym, Secuado |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.